In this article, they employed microglia-based phenotypic screenings to search for small molecules that modulate the release of detrimental proinflammatory cytokines and they identified a novel pharmacological inhibitor of neuroinflammation (named GIBH-130) which was validated to alter phenotypes of neuroinflammation in AD brains.

“Currently, anti-Alzheimer’s Disease (AD) drug discovery using target-based approaches is extremely challenging due to unclear etiology of AD and absence of validated therapeutic protein targets. Neuronal death, regardless of causes, plays a key role in AD progression, and it is directly linked to neuroinflammation. Meanwhile, phenotypic screening is making a resurgence in drug discovery process as an alternative to target-focused approaches.”

Source : http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00125